Clinical outcome of the small-cell carcinoma (all p16-positive) patients was also significantly shorter than that of p16-positive (P = 0.023) as well as that of p16-negative high-grade squamous cell carcinoma patients (P < 0.001) (Fig. 4). This evidence concerns the gene CDKN2A and squamous cell carcinoma.